3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
pembrolizumab
59
Carboplatin
56
Pemetrexed
47
Cisplatin
39
Paclitaxel
24
Nivolumab
23
Docetaxel
21
durvalumab
20
Gemcitabine
15
130-nm albumin-bound paclitaxel
14
osimertinib
13
Cetuximab
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
amivantamab
8
Taxes
8
Radiotherapy
8
Radiosurgery
7
Ipilimumab
7
lazertinib
6
alectinib
6
Ramucirumab
6
Observation
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
Etoposide
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
olaparib
×
30 days
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled